BRIEF published on 12/11/2025 at 07:05, 8 days ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
BRIEF published on 12/11/2025 at 07:05, 8 days ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE published on 12/11/2025 at 07:00, 8 days ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 1 month 9 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 1 month 9 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 1 month 9 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 1 month 13 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 1 month 13 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 1 month 13 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 month 14 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
Published on 12/19/2025 at 03:15, 4 hours 26 minutes ago Tactical Resources Announces Receipt Of Final Order Approving Arrangement With Plum Acquisition Corp. III
Published on 12/19/2025 at 01:10, 6 hours 31 minutes ago Ostrom Climate Exits Existing UPRIIS ERPA Arrangements
Published on 12/19/2025 at 01:00, 6 hours 41 minutes ago Sun Peak Metals Announces Completion of Acquisition of Saudi Discovery Company SPV Limited
Published on 12/19/2025 at 00:50, 6 hours 51 minutes ago High Resolution Gravity Survey Targets Challenger Repeats
Published on 12/19/2025 at 00:00, 7 hours 41 minutes ago LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/19/2025 at 07:15, 26 minutes ago OPPO Collaborates with UNESCO, Leveraging Tablets to Empower Educational Equity and Digital Inclusion in Asia and Africa
Published on 12/19/2025 at 07:10, 31 minutes ago Deutsche Konsum REIT-AG publishes full year 2024/2025 results
Published on 12/19/2025 at 07:00, 41 minutes ago From Global Awards to a Global Stage: OPPO Photography Awards 2025 Conclude with Finale Exhibition in Egypt
Published on 12/19/2025 at 07:00, 41 minutes ago Branicks Group AG: Sale of the SAP Tower in Eschborn
Published on 12/19/2025 at 07:00, 41 minutes ago HORNBACH increases sales and market share in 9M 2025/26 and Q3 – adjusted EBIT down EUR 7.3 million in Q3, 9M at previous year’s level
Published on 12/19/2025 at 07:00, 41 minutes ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 41 minutes ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 13 hours 11 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 13 hours 11 minutes ago Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 13 hours 56 minutes ago Cie du Bois Sauvage: Vernietiging eigen aandelen
